Centessa Financial Statements From 2010 to 2025

CNTA Stock  USD 16.96  0.37  2.23%   
Centessa Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Centessa Pharmaceuticals PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Centessa Pharmaceuticals financial statements helps investors assess Centessa Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Centessa Pharmaceuticals' valuation are summarized below:
Gross Profit
6.9 M
Market Capitalization
2.2 B
Enterprise Value Revenue
262.0426
Revenue
6.9 M
Earnings Share
(1.52)
We have found one hundred twenty available fundamental signals for Centessa Pharmaceuticals PLC, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Centessa Pharmaceuticals PLC prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 992.8 M. The current year's Enterprise Value is expected to grow to about 682.4 M

Centessa Pharmaceuticals Total Revenue

8.27 Million

Check Centessa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Centessa Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 12.6 M, Depreciation And Amortization of 981.9 K or Interest Expense of 12 M, as well as many indicators such as Price To Sales Ratio of 89.37, Dividend Yield of 0.0 or PTB Ratio of 3.06. Centessa financial statements analysis is a perfect complement when working with Centessa Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Centessa Pharmaceuticals Correlation against competitors.

Centessa Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets322.4 M414.3 M148.7 M
Slightly volatile
Short and Long Term Debt Total52.7 M97.3 M26.4 M
Slightly volatile
Total Current Liabilities24.8 M45.3 M12.5 M
Slightly volatile
Long Term Debt61.8 M87.1 M30.1 M
Slightly volatile
Cash And Short Term Investments279.2 M295 M124.5 M
Slightly volatile
Common Stock Shares Outstanding108.4 M110.6 M84.3 M
Slightly volatile
Other Current Assets12.7 M22.3 M5.8 M
Slightly volatile
Other Stockholder Equity621.3 M1.1 B286.5 M
Slightly volatile
Total Liabilities90.3 M142.6 M43.6 M
Slightly volatile
Total Current Assets293.5 M362.4 M135.2 M
Slightly volatile
Short Term Debt3.4 M6.5 M2.4 M
Slightly volatile
Other Current Liabilities19 M31.6 M8.7 M
Slightly volatile
Net Tangible Assets304.6 M386.6 M118.1 M
Slightly volatile
Current Deferred Revenue830.4 K934.2 KM
Slightly volatile
Accounts Payable9.3 M13.6 M4.2 M
Slightly volatile
Cash139.9 M147.2 M92.7 M
Slightly volatile
Non Current Assets Total36 M51.9 M14 M
Slightly volatile
Non Currrent Assets Other2.8 M2.9 M5.9 M
Slightly volatile
Net Receivables23.5 M45 M11.5 M
Slightly volatile
Liabilities And Stockholders Equity397.6 M414.3 M148.4 M
Slightly volatile
Non Current Liabilities Total98 M97.3 M50.4 M
Slightly volatile
Deferred Long Term Liabilities198.4 K223.2 K243.3 K
Slightly volatile
Short and Long Term Debt4.5 M5.1 M5.5 M
Slightly volatile
Net Working Capital352.5 M317.1 M123.6 M
Slightly volatile
Common Stock223 K313.9 K97.4 K
Slightly volatile
Other Liabilities30.2 M34 M37 M
Slightly volatile
Property Plant And Equipment Gross16.2 M15.4 MM
Slightly volatile
Non Current Liabilities Other24.8 K26.1 K2.4 M
Pretty Stable
Property Plant Equipment731.5 K1.3 M397.2 K
Slightly volatile

Centessa Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income12.6 M12 M2.2 M
Slightly volatile
Depreciation And Amortization981.9 K935.1 K253.8 K
Slightly volatile
Interest Expense12 M11.4 M2.8 M
Slightly volatile
Selling General Administrative33.9 M61.8 M16 M
Slightly volatile
Other Operating Expenses119.5 M204.9 M57.1 M
Slightly volatile
Research Development85.7 M143.1 M41 M
Slightly volatile
Total Operating Expenses119.5 M204.9 M57.1 M
Slightly volatile
Selling And Marketing Expenses517.2 K544.4 K32.3 M
Slightly volatile
Cost Of Revenue949.8 K904.6 K198.7 K
Slightly volatile

Centessa Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings88.9 M84.7 M27.1 M
Slightly volatile
Stock Based Compensation35.5 M33.8 M8.8 M
Slightly volatile
Begin Period Cash Flow475.3 M452.7 M129.2 M
Slightly volatile
Other Cashflows From Financing Activities265.1 K279 K42.3 M
Pretty Stable
Depreciation978.1 K931.5 K186.2 K
Slightly volatile
Capital Expenditures184.6 K194.3 K244.8 K
Pretty Stable
Total Cash From Financing Activities23.1 M24.3 M51.3 M
Pretty Stable
End Period Cash Flow250.9 M147.2 M105.5 M
Slightly volatile
Change To Netincome20.1 M21.1 M20.8 M
Slightly volatile
Dividends Paid528.1 K594.1 K647.7 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio89.37101110
Slightly volatile
Days Sales Outstanding1.7 K1.9 KK
Slightly volatile
Average Payables5.9 M9.5 M5.4 M
Slightly volatile
Stock Based Compensation To Revenue3.433.864.2084
Slightly volatile
Capex To Depreciation0.230.244.6879
Slightly volatile
EV To Sales84.394.84103
Slightly volatile
Payables Turnover0.00560.00850.0056
Slightly volatile
Sales General And Administrative To Revenue6.277.067.6936
Slightly volatile
Research And Ddevelopement To Revenue14.5216.3417.8129
Slightly volatile
Capex To Revenue0.01980.02220.0242
Slightly volatile
Cash Per Share2.712.41.1978
Slightly volatile
Days Payables Outstanding64.3 K44.4 K70.4 K
Slightly volatile
Income Quality0.991.221.0664
Slightly volatile
Net Debt To EBITDA0.220.240.3315
Slightly volatile
Current Ratio8.747.24.5381
Slightly volatile
Receivables Turnover0.140.160.1719
Slightly volatile
Graham Number9.278.394.3304
Slightly volatile
Capex Per Share0.00190.0020.0027
Pretty Stable
Revenue Per Share0.0570.06410.0699
Slightly volatile
Interest Debt Per Share0.540.880.285
Slightly volatile
Debt To Assets0.280.270.3965
Slightly volatile
Days Of Payables Outstanding64.3 K44.4 K70.4 K
Slightly volatile
Ebt Per Ebit1.090.931.1155
Pretty Stable
Long Term Debt To Capitalization0.140.220.1485
Slightly volatile
Quick Ratio9.027.24.5699
Slightly volatile
Net Income Per E B T1.090.991.0257
Slightly volatile
Cash Ratio3.553.743.3866
Slightly volatile
Days Of Sales Outstanding1.7 K1.9 KK
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0171
Slightly volatile
Fixed Asset Turnover0.420.480.5192
Slightly volatile
Debt Ratio0.280.270.3965
Slightly volatile
Price Sales Ratio89.37101110
Slightly volatile
Asset Turnover0.01520.01710.0187
Slightly volatile

Centessa Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap992.8 M880.4 M1.3 B
Slightly volatile

Centessa Fundamental Market Drivers

Cash And Short Term Investments256.5 M

Centessa Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Centessa Pharmaceuticals Financial Statements

Centessa Pharmaceuticals stakeholders use historical fundamental indicators, such as Centessa Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Centessa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Centessa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Centessa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Centessa Pharmaceuticals PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue934.2 K830.4 K
Total Revenue7.9 M8.3 M
Cost Of Revenue904.6 K949.8 K
Stock Based Compensation To Revenue 3.86  3.43 
Sales General And Administrative To Revenue 7.06  6.27 
Research And Ddevelopement To Revenue 16.34  14.52 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.06  0.06 
Ebit Per Revenue(22.49)(23.62)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:
Check out the analysis of Centessa Pharmaceuticals Correlation against competitors.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
0.065
Return On Assets
(0.20)
Return On Equity
(0.43)
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.